Which services can Taiho Oncology Patient Support help with?

We help with billing, coding, benefit verifications, prior authorizations, insurance denial appeals, follow-ups and reminders, and specialty pharmacy coordination. For eligible patients, we also offer personalized nurse support upon request.

How can HCPs enroll patients in the program?

The first step is to register your practice if you have not already done so. Then, you can enroll your patients in one of 3 ways: 1) Fax a Patient Enrollment Form that has been completed and signed by the patient and HCP to 1‑844‑287‑2559; ​2) Complete a Patient Enrollment Form online (NOTE: Patients can do this and bring it to their HCP's office, or HCPs can complete the form); or 3) Call 1‑844‑TAIHO‑4U (1‑844‑824‑4648) for help with enrollment.

As an HCP, can I tell my patients to contact Taiho Oncology Patient Support?

Yes. Patients can contact us directly about how to access their medication. We will help eligible patients with alternate funding, such as the Taiho Oncology Patient Support Co‑Pay Card, our Patient Assistance Program, and referrals to nonprofit foundations.

Can patients be referred to Taiho Oncology Patient Support for eligibility or prior authorization issues, assistance with treatment plan support (including refill reminders), and education by a nurse?

Yes. If selected on the Patient Enrollment Form, our Nurse Navigators are available to eligible patients 24 hours a day, 7 days a week. Our Reimbursement Specialists provide personalized, responsive support services.

What are the income and other eligibility criteria patients must meet to qualify for the Taiho Oncology Patient Support Co-pay Card?

Please call the resource center at 1‑844‑TAIHO‑4U (1‑844‑824‑4648) to learn about patient eligibility criteria.

Do I have to use specific specialty pharmacies?

LONSURF® (trifluridine and tipiracil) tablets are available through the following specialty pharmacies: Accredo, Avella, Biologics, CVS/Caremark, , Onco360, and Walgreens. It is also available to self-dispensing practices and hospital retail pharmacies through ASD Healthcare, McKesson Specialty Health, McKesson Plasma and Biologics, and Oncology Supply. Contact your LONSURF representative or call Taiho Oncology Patient Support at 1‑844‑TAIHO‑4U (1‑844‑824‑4648) for further information.

What are the eligibility criteria of the independent co-pay assistance foundations?

The co-pay assistance foundations to which we refer patients have their own criteria for patient eligibility, including financial eligibility. Taiho Oncology does not influence or control the decisions of these foundations, but Taiho Oncology Patient Support can assist patients by making an appropriate referral based on a patient's diagnosis. We cannot guarantee financial assistance once a patient has been referred. Healthcare professionals may contact these foundations directly or receive assistance identifying which foundations might be options for a given patient. Please call the resource center at 1‑844‑TAIHO‑4U (1‑844‑824‑4648).

As an HCP, how can the online provider portal help me?

The online provider portal is an all-in-one solution for managing your patients on LONSURF® (trifluridine and tipiracil) tablets. You can see all your enrolled patients on the patient dashboard, and easily search for more detailed information such as a list of other providers treating the patient, prescription refill history and more. From the portal, you can also fill out a Patient Enrollment Form, view a sample Letter of Medical Necessity, find specialty pharmacy contact info, and get answers to frequently asked questions. Importantly, the portal features a link to request a Reimbursement Specialist to contact you directly.

Indication and Important Safety Information +


LONSURF® (trifluridine and tipiracil) tablets are indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild type, an anti-EGFR therapy.



Severe Myelosuppression: In Study 1, LONSURF caused severe and life‑threatening myelosuppression (Grade 3‑4) consisting of anemia (18%), neutropenia (38%), thrombocytopenia (5%), and febrile neutropenia (3.8%). One patient (0.2%) died due to neutropenic infection. In Study 1, 9.4% of LONSURF‑treated patients received granulocyte‑colony stimulating factors.

Obtain complete blood counts prior to and on day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for febrile neutropenia, Grade 4 neutropenia, or platelets less than 50,000/mm3. Upon recovery, resume LONSURF at a reduced dose as clinically indicated.

Embryo‑Fetal Toxicity: LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LONSURF.


Lactation: It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breast‑fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.

Male Contraception: Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose.

Geriatric Use: Patients 65 years of age or over who received LONSURF had a higher incidence of the following compared to patients younger than 65 years: Grade 3 or 4 neutropenia (48% vs 30%), Grade 3 anemia (26% vs 12%), and Grade 3 or 4 thrombocytopenia (9% vs 2%).

Hepatic Impairment: Patients with severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST) were not studied. No adjustment to the starting dose of LONSURF is recommended for patients with mild hepatic impairment. Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin greater than 1.5 times ULN and any AST) hepatic impairment.

Renal Impairment: In Study 1, patients with moderate renal impairment (CLcr=30 to 59 mL/min, n=47) had a higher incidence (difference of at least 5%) of ≥Grade 3 adverse events, serious adverse events, and dose delays and reductions compared to patients with normal renal function (CLcr ≥90 mL/min, n=306) or patients with mild renal impairment (CLcr=60 to 89 mL/min, n=178).

Patients with moderate renal impairment may require dose modifications for increased toxicity. Patients with severe renal impairment were not studied.


Most Common Adverse Drug Reactions in Patients Treated With LONSURF (≥5%): The most common adverse drug reactions in LONSURF‑treated patients vs placebo‑treated patients with refractory mCRC, respectively, were asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), abdominal pain (21% vs 18%), pyrexia (19% vs 14%), stomatitis (8% vs 6%), dysgeusia (7% vs 2%), and alopecia (7% vs 1%).

Additional Important Adverse Drug Reactions: The following occurred more frequently in LONSURF‑treated patients compared to placebo: infections (27% vs 15%) and pulmonary emboli (2% vs 0%).

The most commonly reported infections which occurred more frequently in LONSURF‑treated patients were nasopharyngitis (4% vs 2%) and urinary tract infections (4% vs 2%).

Interstitial lung disease (0.2%), including fatalities, has been reported in clinical studies and clinical practice settings in Asia.

Laboratory Test Abnormalities in Patients Treated With LONSURF: Laboratory test abnormalities in LONSURF‑treated patients vs placebo-treated patients with refractory mCRC, respectively, were anemia (77% vs 33%), neutropenia (67% vs 1%), and thrombocytopenia (42% vs 8%).

Please see full Prescribing Information.